Quanta Therapeutics
South San Francisco, US · 4 known investors
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.
Founders & leadership
CP
Cameron PittNamed on SEC filing
YH
Ying HuangNamed on SEC filing
DM
Derek MetzgerNamed on SEC filing
Board
MK
Maha KatabiBoard director
PN
Perry NisenBoard director
MF
Maria FardisBoard director
RJ
Rajul JainBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements▶$76.2MraisedJun 2026 · 17 investors · BiotechnologyRule 506(b)
▶$76.2MraisedJun 2026 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maha KatabiDirector
- Perry NisenExecutive Officer, Director
- Cameron PittExecutive Officer, Director
- Maria FardisDirector
- Ying HuangDirector
- Derek MetzgerExecutive Officer
- Rajul JainDirector
- Offering amount
- $89.1M
- Amount sold
- $76.2M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedFeb 2023 · 9 investors · BiotechnologyRule 506(b)
▶$30MraisedFeb 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arjun GoyalDirector
- Cameron PittExecutive Officer, Director
- Ying HuangDirector
- Perry NisenExecutive Officer, Director
- Samuel SaksDirector
- Leonardo FaoroExecutive Officer
- Maria FardisDirector
- Maha KatabiDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$40.2MraisedNov 2021 · 10 investors · BiotechnologyRule 506(b)
▶$40.2MraisedNov 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cameron PittDirector
- Maha KatabiDirector
- Perry NisenExecutive Officer, Director
- Maria FardisDirector
- Samuel SaksDirector
- Arjun GoyalDirector
- Offering amount
- $70.2M
- Amount sold
- $40.2M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Quanta13 shared keywordsQuanta develops the Quanta Dialysis System, a compact, modular hemodialysis machine designed for flexible kidney care in acute and chronic facilities. The device targets dialysis patients and providers with a self-care-capable design intended to lower operational costs while delivering clinical performance.
Kite Pharma12 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Companies competing with Quanta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Quanta Therapeutics do?
- Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.
- Who are Quanta Therapeutics's investors?
- Quanta Therapeutics's investors include Longitude Capital, Sofinnova Ventures, Vida Ventures, Frazier Life Sciences.
- Where is Quanta Therapeutics headquartered?
- Quanta Therapeutics is headquartered in South San Francisco, US.